BlogHotel.orgAccueil | Créer un blog | Imprimer la page Imprimer | Blog hasard Au hasard | Chercher des blogs Rechercher | Entrer dans le chat du blog Chat | | Jeux Jeux | Adminitration et édition du Blog Manager

freemexy Accueil | Profil | Archives | Amis
freemexy

Global Tulobuterol Hydrochloride Market Top Vendors8/11/2019
The global market size of Tulobuterol Hydrochloride is $XX million in 2018 with XX CAGR from 2014 to 2018, and it is expected to reach $XX million by the end of 2024 with a CAGR of XX% from 2019 to 2024.wisepoqder Tulobuterol hydrochloride

Global Tulobuterol Hydrochloride Market Report 2019 – Market Size, Share, Price, Trend and Forecast is a professional and in-depth study on the current state of the global Tulobuterol Hydrochloride industry. The key insights of the report:

1.The report provides key statistics on the market status of the Tulobuterol Hydrochloride manufacturers and is a valuable source of guidance and direction for companies and individuals interested in the industry.

2.The report provides a basic overview of the industry including its definition, applications and manufacturing technology.

3.The report presents the company profile, product specifications, capacity, production value, and 2013-2018 market shares for key vendors.

4.The total market is further divided by company, by country, and by application/type for the competitive landscape analysis.

5.The report estimates 2019-2024 market development trends of Tulobuterol Hydrochloride industry.

6.Analysis of upstream raw materials, downstream demand, and current market dynamics is also carried out

7.The report makes some important proposals for a new project of Tulobuterol Hydrochloride Industry before evaluating its feasibility.

There are 4 key segments covered in this report: competitor segment, product type segment, end use/application segment and geography segment.

For competitor segment, the report includes global key players of Tulobuterol Hydrochloride as well as some small players.

0 Commentaires | poster un commentaire | Lien Permanent

Selective Estrogen Receptor Modulators (SERMs)8/11/2019
Raloxifene Powder (Evista) belongs to a class of drugs called selective estrogen receptor modulators (SERMs). It is FDA-approved for the prevention and treatment of osteoporosis in postmenopausal women and to reduce risk of invasive breast cancer in postmenopausal women at high risk or with osteoporosis.

SERMs were developed to reap the benefits of estrogen while avoiding the hormone's potential side effects. Raloxifene, a so-called ''designer'' estrogen, can act like estrogen on bone -- protecting its density -- but as an anti-estrogen on the lining of the uterus.wisepoqder Raloxifene powder

In a three-year study involving some 600 postmenopausal women, raloxifene was found to increase bone density and lower LDL cholesterol, while having no stimulative effect on the uterine lining (which means that it is unlikely to cause uterine cancer).

The first SERM to reach the market was tamoxifen, which blocks the stimulative effect of estrogen on breast tissue. Tamoxifen has proven valuable in preventing cancer in the second breast of women who have had cancer in one breast.Because of its anti-estrogen effects, the most common side effects with raloxifene are hot flashes. Conversely, because of its estrogenic effects, raloxifene increases the risk of blood clots, including deep vein thrombosis (DVT) and pulmonary embolism (blood clots in the lung). Studies show that the risk of blood clots over a five year period is less than 1% for women who did not have a history of blood clots. Patients taking raloxifene should avoid tobacco use and prolonged periods of immobility during travel, when blood clots are more prone to occur.

The risk of deep vein thrombosis with raloxifene is probably comparable to that of estrogen, about 2 to 3 times higher than the usual low occurrence rate. Raloxifene also increases the risk of stroke death in women who have heart disease or risk factors for heart disease.
Raloxifene decreases the risk of spine fractures in postmenopausal women with osteoporosis, But it does not appear to decrease the risk of hip fracture. (The only agents that are definitely proven to decrease hip fracture risk are bisphosphonates.)

Another SERM combination drug, bazedoxifene-conjugated estrogen (Duavee) is FDA-approved to reduce hot flashes and osteoporosis in postmenopausal women.

0 Commentaires | poster un commentaire | Lien Permanent

Page 203 of 834
Précédent | Suivant